September 10, 2020
6 min read
Tag: Precision
Summa Equity Acquires Sengenics to Advance Precision Medicine Through Proteomics
Summa Equity, the purpose-driven private equity firm that invests to solve global challenges, has acquired a majority stake in Sengenics, a functional proteomics company with a proprietary technology called KREX that enables researchers to vastly improve the understanding of the human proteome and immune system. Proteomics, i.e. the large-scale study of proteins, is one of the most important areas for gaining insights into human biology and disease, as protein expressions, structures and functions are critical in reflecting states of health.
Sengenics was first founded in 2008 and went on to commercialise the KREX technology that was originally developed from a joint collaboration between the University of Cambridge and the University of Oxford. The company’s patented KREX technology enables researchers to address both the function and folding structure of proteins using one technology that allows for large numbers of proteins to be studied simultaneously, with high sensitivity and specificity. The combination
SEngine Precision Medicine to Present at Society of Functional Precision Medicine Virtual …
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) — SEnginePrecision Medicine, a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on patient-derived tumor organoids, today announced that Chief Medical Officer Astrid L. Margossian, MD, PhD, will present at the Society for Functional Precision Medicine (SFPM) Virtual Monthly Seminar on October 14th at 11:30 am ET.
Dr. Margossian is leading SEngine’s clinical validation initiatives for the PARIS® Test, a CLIA certified cancer organoid based drug sensitivity test for all solid tumors. The presentation is entitled, “Predictive Clinical Value of a CLIA-Approved Organoid Based Drug Sensitivity Test,” and will highlight the data on the PARIS® Test, recently presented at the ASCO 2020 and ACCR 2020 annual meetings, inclusive of organoids sensitivity results, showing clinical correlation with genomics and previous
Scientists develop new ‘precision medicine’ approach to treating damaged DNA in pancreatic cancer
Scientists have developed a new “precision medicine” approach to treating the damaged DNA in the cancer cells of Pancreatic Cancer patients.
The findings mark an important step forward for potential treatment options for pancreatic cancer, improving the options and outcomes for a disease where survival rates have remained stubbornly low.
The study detailing the approach—led by the University of Glasgow and published in Gastroenterology—used cell lines and organoids that were generated from patients with pancreatic cancer to develop new molecular markers that can predict who will respond to drugs targeting DNA damage.
The researchers tested these markers using multiple drugs, and have developed a strategy that are now being taken forward into clinical trial. The trial will help doctors and researchers predict which patient will respond to which one of these drugs, either alone or in combination.
Funding for the trail has come from AstraZeneca
Progenity to Present Precision Medicine Abstracts at American College of Gastroenterology (ACG) …
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, is pleased to announce that two abstracts related to Progenity’s ingestible technologies for the diagnosis and treatment of gastrointestinal disorders have been accepted for presentation at American College of Gastroenterology (ACG) virtual annual meeting set to take place October 23-28, 2020. Progenity will be presenting one oral presentation and one poster presentation.
The accepted abstract titles and study findings will be a part of the event’s on-demand sessions and virtual e-poster hall, which are embargoed until October 26
Precision medicine uses multiomic details to battle kidney disease
Source/Disclosures
Disclosures:
Bansal, Eadon, Jones-Smith, Kiryluk, and Sharma report no relevant financial disclosures.
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]
The value of precision medicine has been shown with the identification of the genetic causes of tumors that differ among patients. Applied to nephrology, precision medicine can offer an earlier look at the potential risk for kidney disease.
“Precision medicine is a personalized approach to disease management of the patient … The goal is to have the right dose, delivered at the right time,
How Precision Medicine Can Unravel How We Treat COVID
By Colin Allen and David Feingold, The Conversation
Tom Hanks and his wife, Rita Wilson, were among the earliest celebrities to catch the novel coronavirus. In an interview at the beginning of July, Hanks described how differently COVID-19 had affected each of them in March.
“My wife lost her sense of taste and smell, she had severe nausea, she had a much higher fever than I did. I just had crippling body aches,” he said. “I was very fatigued all the time and I couldn’t concentrate on anything for more than about 12 minutes.”
Why does COVID-19 present such different symptoms—or none at all—in different people?
Pre-existing conditions can only be part of the story. Hanks is over 60 and is a Type 2 diabetic, putting him in a high-risk group. Nevertheless, he survived his brush with the virus with no pneumonia and apparently without any long-lasting effects. Knowing what
Global Precision Medicine Market 2020-2030: Focus on Ecosystem, Technology, Application, and Competitive Landscape
The “Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape – Analysis and Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.
Global Precision Medicine Market to Reach $278.61 Billion by 2030
Precision medicine refers to the medicine developed as per an individual’s genetic profile. It provides guidance regarding the prevention, diagnosis, and treatment of diseases. The segmentation of the population is done depending on the genome structure of the individuals and their compatibility with a specific drug molecule.
In the precision medicine market, the application of molecular biology is to study the cause of a patient’s disease at the molecular level, so that target-based therapies or individualized therapies can be applied to cure the patient’s health-related problems.
This industry is gaining traction due to the increasing awareness about healthcare among individuals, integration of smart devices such as smartphones and tablets into healthcare,
Global Precision Medicine Market 2020-2030: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
The MarketWatch News Department was not involved in the creation of this content.
Dublin, Sep 30, 2020 (GLOBE NEWSWIRE via COMTEX) —
Dublin, Sept. 30, 2020 (GLOBE NEWSWIRE) — The “Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape – Analysis and Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.
Global Precision Medicine Market to Reach $278.61 Billion by 2030
Precision medicine refers to the medicine developed as per an individual’s genetic profile. It provides guidance regarding the prevention, diagnosis, and treatment of diseases. The segmentation of the population is done depending on the genome structure of the individuals and their compatibility with a specific drug molecule.
In the precision medicine market, the application of molecular biology is to study the cause of a patient’s disease at the molecular level, so that target-based therapies or individualized therapies can be applied to cure
Global Precision Medicine Market 2020 with (COVID-19) Impact Analysis, Product Type, Application, Key Manufacturers, Regions and Forecast to 2025
The MarketWatch News Department was not involved in the creation of this content.
Sep 29, 2020 (CDN Newswire via Comtex) —
A wide-ranging analysis report titled Global Precision Medicine Market 2020 by Company, Regions, Type and Application, Forecast to 2025 provides a brief overview of the market covering the scope, size, disposition, and growth of the industry. The report presents an estimate of the current market scenario and data related to the competitive landscape of the industry. It delivers five-year industry forecasts, growth rates, and an analysis of the industry key players and their market shares. The report shows information regards to several regions that have successfully established its position in the global Precision Medicine market. The geographical and competitive dynamics of this global market will help you get a comprehensive picture of the market.
An industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful
